Introduction
Glucagon when given intravenously to patients with Paget's disease of bone results in relief of bone pain and a rapid fall in serum alkaline phosphatase, urinary calcium and hydroxyproline (Condon, 1971) ; calcitonin (Bijvoet and Jansen, 1967; Bijvoet, van der Sluys Veer and Jansen, 1968; Haddad, Birge and Avioli, 1970) ; and mithramycin (Ryan, Schwartze, and Perlia, 1969; Condon et al., 1971 ) also induces clinical and biochemical remissions in Paget's disease.
The authors treated 12 patients with various combinations of these therapeutic agents and, since all had similar responses to the therapy, 4 subjects were selected for detailed appraisal. (Fiske and Subbarow, 1925) ; and urinary hydroxyproline estimated using a specific assay procedure (Karl, Laitinen and Prockop, 1967 A further period of .v. glucagon resulted in a fall in alkaline phosphatase to normal and treatment was discontinued for 16 days. All biochemical parameters rose but rapidly returned to normal after a mithramycin infusion followed by calcitonin and glucagon subcutaneously. Case 3 (Fig. 3) A 69-year-old man with severe bone pain was treated initially with i.v. glucagon. There (Fig. 4) A 74-year-old man presented with bone pain and a sabre deformity of the left tibia. Treatment with i.v. glucagon caused a marked fall in serum phosphate, alkaline phosphatase, urinary calcium and hydroxyproline. These criteria of activity levelled out when subcutaneous calcitonin was given alone. Addition of glucagon resulted in all biochemical parameters returning to normal (Fig. 4) .
Discussion
The aim of treatment of Paget's disease of bone is to relieve bone pain, prevent development of bone deformity, reduce the incidence of fractures and nerve compression, decrease hypercalciuria (which can lead to renal calculi) and control 'high output' cardiac failure by reducing blood flow through diseased bone. These criteria should be attained as rapidly as possible and calcitonin, glucagon, mithramycin and actinomycin have been used therapeutically. A 4th group of drugs, the diphosphonates, are also effective in Paget's disease of bone (Smith, Russel and Bishop, 1971; Frijlink et al., 1979) but some of these compounds may cause osteomalacia (Fleisch et al., 1970) 
